NARS1 and melanoma: In the POLARIS‐01 trial, which was conducted in Asian advanced melanoma patients, the ORR of NRAS‐mutant cohort receiving toripalimab was only 6.1%, indicating NARS mutation a potential resistance mechanism for immunotherapy.37